MacroGenics Inc (MGNX) stock
Close on Nov 11, 2026Market cap $147.78MP/E –Yield –
MacroGenics Inc grew revenue 11.7% to $167.67M over the twelve months to Jun 30, 2026. Free cash flow was -$65.54M. At the latest close the market valued the company at $147.78M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $147.78M
- P/E ratio
- –
- Price to sales
- 0.88
- Price to book
- 3.45
- Dividend yield
- –
- Free cash flow yield
- -44.35%
Fundamentals
- Revenue
- $167.67M
- Net income
- -$14.59M
- EPS, diluted
- -$0.22
- Free cash flow
- -$65.54M
- Book value per share
- $0.67
- Diluted shares
- 64M
Trading
- Next earnings
- Nov 11, 2026 (estimated, after the close)
- Previous close
- $2.42
- Open
- $2.42
- Day's range
- $2.32 – $2.42
- Volume
- 451,230
- Average volume (20 days)
- 1,039,284
- Index membership
- Russell 2000 (since Jun 2026)
- Beta (5 years)
- 1.72
- 52-week range
- $1.32 – $5.08
- RSI (14 days)
- 34.5
- Volatility (1 year)
- 91.8%
- Relative volume
- 0.63×
- WACC
- 13.5%
On 1 of our idea list: More cash than they're worth
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2013, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | MGNX | S&P 500 | Difference | MGNX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -38.0% | -2.4% | −35.6 pts | ||
| 3 months | -40.8% | -1.2% | −39.7 pts | ||
| Year to date | +44.1% | +12.3% | +31.8 pts | ||
| 1 year | +52.6% | +12.4% | +40.2 pts | ||
| 3 years | -63.8% | +78.8% | −142.6 pts | -28.7% | +21.4% |
| 5 years | -88.4% | +75.2% | −163.6 pts | -35.0% | +11.9% |
| 10 years | -92.2% | +311.1% | −403.3 pts | -22.5% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases MacroGenics filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- News
- News
- Results
- News
- Update
About MacroGenics
Pharmaceutical Preparations
MacroGenics, Inc. is a clinical-stage biopharmaceutical company that develops antibody-based therapeutics for cancer treatment. Utilizing proprietary multi-specific platforms such as DART and TRIDENT alongside licensed antibody-drug conjugate technologies, the company designs therapeutics for solid tumors and hematologic malignancies. Its pipeline includes investigational candidates like lorigerlimab, MGC026, and MGC028. Beyond proprietary drug development, the company generates revenue and collaborative funding by out-licensing product candidates to global biopharmaceutical partners and providing contract development and manufacturing services to external clients and commercial collaborators.
Company profile, executives and historyMacroGenics stock: common questions
What is MacroGenics's stock price?
MGNX closed at $2.32 on Nov 11, 2026, down 4.13% on the day. Over the past 52 weeks it traded between $1.32 and $5.08.
What is MacroGenics's market cap?
MacroGenics was worth $147.78M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is MGNX's P/E ratio?
MacroGenics lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.22), so it has no meaningful P/E ratio.
How much revenue does MacroGenics make?
MacroGenics reported revenue of $167.67M for the twelve months to Jun 30, 2026, up 11.7% from a year earlier.
Does MacroGenics pay a dividend?
No. MacroGenics has not paid a cash dividend over the last twelve months.
When does MacroGenics report earnings next?
MacroGenics is expected to report Q3 FY2026 results on Nov 11, 2026, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has MGNX stock performed over the past year?
Including dividends, MGNX returned +52.6% over the past year, against +12.4% for the S&P 500.
How many MGNX shares are sold short?
5M shares were sold short at the latest FINRA report, 8.28% of the float, or 3.9 days of average trading volume.
Who are MacroGenics's competitors?
Companies most similar to MacroGenics by business, industry and size include XNCR, RCUS, ANAB, NUVB, LGND.
See a number that looks wrong?